David E Gerber Selected Research

Radiotherapy

8/2023	Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors.
7/2021	Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer.
1/2021	Upfront Brain Treatments Followed by Lung Surgery Improves Survival for Stage IV Non-small Cell Lung Cancer Patients With Brain Metastases: A Large Cohort Analysis.
1/2018	Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
1/2018	Development and Validation of a Nomogram Prognostic Model for SCLC Patients.
1/2017	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).
9/2015	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
3/2015	Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies.
12/2014	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
10/2013	Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David E Gerber Research Topics

Disease

82	Neoplasms (Cancer) 01/2024 - 03/2006
57	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 12/2008
35	Lung Neoplasms (Lung Cancer) 01/2024 - 11/2009
12	Disease Progression 07/2022 - 12/2014
6	Pancreatic Neoplasms (Pancreatic Cancer) 07/2017 - 02/2008
5	Exanthema (Rash) 01/2024 - 02/2008
4	Autoimmune Diseases (Autoimmune Disease) 01/2023 - 11/2016
4	Brain Neoplasms (Brain Tumor) 01/2022 - 05/2007
3	Infections 11/2023 - 01/2023
3	Pneumonia (Pneumonitis) 01/2023 - 01/2017
3	Diarrhea 11/2022 - 10/2017
3	Nausea 11/2022 - 12/2015
3	Lymphoma (Lymphomas) 03/2022 - 05/2007
3	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2007
3	Neoplasm Metastasis (Metastasis) 07/2021 - 01/2019
3	Adenocarcinoma 11/2020 - 08/2013
3	Necrosis 10/2018 - 11/2015
3	Glioma (Gliomas) 04/2007 - 01/2007
2	Melanoma (Melanoma, Malignant) 01/2023 - 01/2023
2	Myocarditis (Carditis) 01/2023 - 01/2020
2	Vomiting 11/2022 - 12/2015
2	Venous Thromboembolism 11/2022 - 08/2008
2	Mouth Neoplasms (Oral Cancer) 01/2021 - 11/2019
2	Carcinogenesis 01/2021 - 01/2017
2	Adenocarcinoma of Lung 10/2020 - 12/2015
2	Fatigue 01/2020 - 10/2017
2	Head and Neck Neoplasms (Head and Neck Cancer) 11/2015 - 03/2010
2	Hemorrhage 08/2014 - 08/2008
1	Hodgkin Disease (Hodgkin's Disease) 01/2024
1	Neutropenia 01/2024
1	Prostatic Neoplasms (Prostate Cancer) 01/2023
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2023
1	Hypertriglyceridemia 01/2023
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023
1	Skin Diseases (Skin Disease) 01/2023

Drug/Important Bio-Agent (IBA)

24	Immune Checkpoint InhibitorsIBA 08/2023 - 01/2016
10	Biomarkers (Surrogate Marker)IBA 01/2024 - 11/2017
9	NivolumabIBA 01/2024 - 10/2015
7	Tyrosine Kinase InhibitorsIBA 03/2022 - 08/2011
7	Monoclonal AntibodiesIBA 01/2015 - 04/2007
6	PlatinumIBA 01/2023 - 03/2015
6	CytokinesIBA 03/2022 - 09/2010
6	ErbB Receptors (EGF Receptor)IBA 01/2022 - 12/2008
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 08/2011
5	AntibodiesIBA 11/2023 - 01/2019
5	Docetaxel (Taxotere)FDA Link 01/2023 - 10/2015
5	Carboplatin (JM8)FDA LinkGeneric 07/2022 - 08/2013
5	Pemetrexed (MTA)FDA Link 07/2022 - 09/2012
5	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 09/2012
5	PhosphatidylserinesIBA 01/2016 - 08/2011
5	bavituximabIBA 01/2016 - 08/2011
4	LigandsIBA 01/2022 - 10/2015
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2010
4	Bevacizumab (Avastin)FDA Link 11/2020 - 09/2012
4	beta-lapachoneIBA 10/2018 - 11/2015
3	AutoantibodiesIBA 01/2024 - 01/2020
3	IpilimumabIBA 01/2024 - 01/2017
3	durvalumabIBA 12/2023 - 01/2020
3	pembrolizumabIBA 01/2023 - 01/2021
3	Circulating Tumor DNAIBA 03/2022 - 01/2021
3	brigatinibIBA 03/2022 - 02/2017
3	VaccinesIBA 11/2020 - 05/2013
3	AntigensIBA 11/2020 - 04/2007
3	Anaplastic Lymphoma KinaseIBA 03/2019 - 12/2015
3	NAD (NADH)IBA 01/2019 - 11/2015
3	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 07/2015
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2017 - 11/2012
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013 - 09/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2023 - 03/2022
2	Messenger RNA (mRNA)IBA 10/2020 - 01/2014
2	CTLA-4 AntigenIBA 01/2020 - 01/2019
2	Temozolomide (Temodar)FDA LinkGeneric 12/2019 - 01/2007
2	CatalaseIBA 01/2019 - 07/2017
2	Adenosine Triphosphate (ATP)IBA 01/2019 - 11/2015
2	ARQ 197IBA 01/2018 - 08/2011
2	Oxidoreductases (Dehydrogenase)IBA 07/2017 - 11/2015
2	quinone (benzoquinone)IBA 07/2017 - 11/2015
2	Phosphotransferases (Kinase)IBA 01/2017 - 01/2017
2	olaratumabIBA 01/2017 - 11/2012
2	CrizotinibIBA 12/2015 - 02/2015
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2015 - 06/2013
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2013 - 09/2012
1	Epidermal Growth Factor (EGF)IBA 01/2024
1	Brentuximab VedotinIBA 01/2024
1	Complement System Proteins (Complement)IBA 01/2024
1	Iodide Peroxidase (Deiodinase)IBA 01/2023
1	FenretinideIBA 01/2023
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2023
1	bemcentinibIBA 01/2023
1	phospholipid emulsion soybean oil (Intralipid)IBA 01/2023
1	anti-thyroglobulinIBA 01/2023
1	AutoantigensIBA 01/2023

Therapy/Procedure

65	Therapeutics 01/2024 - 01/2007
29	Drug Therapy (Chemotherapy) 01/2024 - 02/2008
17	Immunotherapy 01/2024 - 05/2013
14	Radiotherapy 08/2023 - 01/2007
4	Maintenance Chemotherapy 01/2018 - 02/2011
2	Chemoradiotherapy 01/2022 - 11/2020
2	Precision Medicine 01/2017 - 12/2010
1	Castration 01/2023